Evidence map›Paper›PMID 11274622›Full record

Trial reportThe New England journal of medicine2001

Paroxetine for the prevention of depression induced by high-dose interferon alfa.

D L Musselman, D H Lawson, J F Gumnick, A K Manatunga, S Penna, R S Goodkin, K Greiner, C B Nemeroff, A H Miller

Open access · bronzeAbstract readClinical TrialRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in The New England journal of medicine, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 294 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
294citing papers in PubMed, 6 pooled it
27.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

294 citing papers in PubMed, 6 syntheses or guidelines pooled it, 1,123 citations in OpenAlex.

  1. Pooled it
  2. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2016
    Guideline
  3. KASL clinical practice guidelines: management of hepatitis C.Clinical and molecular hepatology · 2014
    Guideline
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2013
    Trial
  14. Trial
  15. Trial
  16. Trial
  17. Celecoxib or naproxen treatment does not benefit depressive symptoms in persons age 70 and older: findings from a randomized controlled trial.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2012
    Trial
  18. Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Trial
  19. Article
  20. Prevention of late-life depression: a framework and prospectus for research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review

234 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

D L MusselmanDepartment of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA 30322, USA.
D H Lawson
J F Gumnick
A K Manatunga
S Penna
R S Goodkin
K Greiner
C B Nemeroff
A H Miller
Emory University · USCancer Institute (WIA) · IN

Funding

IFN ALPHA-INDUCED DEPRESSIONR01MH060723 · NIMH · EMORY UNIVERSITY · PI MILLER, ANDREW H · 2000 to 2003
$1.4M
NCRR NIH HHS MO1-RR30039NIMH NIH HHS MH00680NIMH NIH HHS MH60723
6 · The paper itself

Abstract

backgroundDepression commonly complicates treatment with the cytokine interferon alfa-2b. Laboratory animals pretreated with antidepressants have less severe depression-like symptoms after the administration of a cytokine. We sought to determine whether a similar strategy would be effective in humans.

methodsIn a double-blind study of 40 patients with malignant melanoma who were eligible for high-dose interferon alfa therapy, we randomly assigned 20 patients to receive the antidepressant paroxetine and 20 to receive placebo. The treatment was begun 2 weeks before the initiation of interferon alfa and continued for the first 12 weeks of interferon alfa therapy.

resultsDuring the first 12 weeks of interferon alfa therapy, symptoms consistent with a diagnosis of major depression developed in 2 of 18 patients in the paroxetine group (11 percent) and 9 of 20 patients in the placebo group (45 percent) (relative risk, 0.24; 95 percent confidence interval, 0.08 to 0.93). Severe depression necessitated the discontinuation of interferon alfa before 12 weeks in 1 of the 20 patients in the paroxetine group (5 percent), as compared with 7 patients in the placebo group (35 percent) (relative risk, 0.14; 95 percent confidence interval, 0.05 to 0.85). The incidence of adverse events was similar in the two groups.

conclusionsIn patients with malignant melanoma, pretreatment with paroxetine appears to be an effective strategy for minimizing depression induced by interferon alfa.

Indexed as

AdultAgedAntidepressive Agents, Second-GenerationAntineoplastic AgentsDepressive DisorderDisease-Free SurvivalDouble-Blind MethodFemaleHumansInterferon-alphaInterferon alpha-2MaleMelanomaMiddle AgedParoxetineRecombinant ProteinsAntidepressive Agents, Second-GenerationAntineoplastic AgentsInterferon-alphaInterferon alpha-2ParoxetineRecombinant ProteinsSelective Serotonin Reuptake Inhibitors

Identifiers

PMID11274622
OpenAlexW2338816059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.